Table 2 Clinical characteristics of patients with MG, overall and stratified by MGFA Class

When patient first experienced MG symptoms, mean (SD) months prior to survey

960

58.7 (67.5)

298

56.2 (71.7)

446

52.3 (58.0)

216

75.4 (76.9)

p < 0.001

When patient was diagnosed with MG, mean (SD) months prior to survey

1115

46.1 (57.4)

331

45.7 (56.8)

519

40.4 (52.3)

265

57.9 (65.6)

p < 0.001

Charlson Comorbidity Index, mean (SD)

1232

0.4 (1.1)

367

0.2 (0.6)

579

0.4 (1.0)

286

0.8 (1.5)

p < 0.001

Concomitant conditions*, n (%)

1232

367

579

286

 Hypertension

346 (28.1)

99 (27.0)

153 (26.4)

94 (32.9)

p = 0.123

 Anxiety

220 (17.9)

50 (13.6)

101 (17.4)

69 (24.1)

p < 0.001

 Dyslipidemia

213 (17.3)

62 (16.9)

100 (17.3)

51 (17.8)

p = 0.947

 Depression

197 (16.0)

44 (12.0)

83 (14.3)

70 (24.5)

p = 0.003

 Diabetes without chronic complications

129 (10.5)

36 (9.8)

59 (10.2)

34 (11.9)

p = 0.663

Number of concomitant conditions, mean (SD)

1232

1.6 (1.7)

367

1.3 (1.4)

579

1.5 (1.6)

286

2.1 (2.0)

p < 0.001

Remission status, n (%)

1232

367

579

286

 Not in remission

213 (17.3)

27 (7.4)

70 (12.1)

116 (40.6)

p < 0.001

 MM/PR/CSR

1019 (82.71)

340 (92.64)

509 (87.91)

170 (59.44)

Proportion of patients who have ever experienced a myasthenic crisis, n (%)

1139

253 (22.2)

341

31 (9.1)

528

111 (21.0)

270

111 (41.1)

p < 0.001

Number of myasthenic crises in 12 months prior to survey, mean (SD)

 Among all patients

1119

0.2 (0.5)

336

0.1 (0.3)

517

0.2 (0.5)

266

0.3 (0.6)

p < 0.001

 Among patients who have experienced a crisis at any point since diagnosis

215

0.9 (0.7)

22

1.0 (0.9)

91

1.0 (0.7)

102

0.88 (0.7)

p = 0.600

Proportion of patients who have experienced MG-related hospitalization at any point since diagnosis, n (%)

1114

537 (48.2)

342

118 (34.5)

518

247 (47.7)

254

172 (67.7)

p < 0.001

Proportion of patients who have experienced MG-related hospitalization in 12 months prior to survey, n (%)

 Among all patients

1082

241 (22.3)

337

35 (10.4)

499

114 (22.9)

246

92 (37.4)

p < 0.001

 Among those who have experienced MG-related hospitalization at any point since diagnosis

505

241 (47.7)

113

35 (31.0)

228

114 (50.0)

164

92 (56.1)

p < 0.001

Number of MG-related hospitalizations in 12 months prior to survey, mean (SD)

 Among all patients

1122

0.3 (0.6)

347

0.1 (0.4)

518

0.3 (0.5)

257

0.5 (0.7)

p < 0.001

 Among patients who have experienced MG-related hospitalization at any point since diagnosis

545

0.5 (0.7)

123

0.3 (0.6)

247

0.6 (0.7)

175

0.7 (0.8)

p < 0.001

Patient has undergone thymectomy, n (%)

1213

244 (20.1)

364

55 (15.1)

564

111 (19.7)

285

78 (27.4)

p < 0.001

Number of maintenance treatment lines received, n (%)

1232

367

579

286

 0 lines

69 (5.6)

28 (7.6)

29 (5.0)

12 (4.2)

p < 0.001

 1 line

717 (58.2)

252 (68.7)

345 (59.6)

120 (42.0)

 2 lines

298 (24.2)

63 (17.2)

140 (24.2)

95 (33.2)

 3 lines

120 (9.7)

19 (5.2)

53 (9.2)

48 (16.8)

 4 or more lines

28 (2.3)

5 (1.4)

12 (2.1)

11 (3.8)

Current/most recent maintenance treatment, n (%)

1163

339

550

274

 Acetylcholinesterases

882 (75.8)

281 (82.9)

409 (74.4)

192 (70.1)

p < 0.001

 Non-steroidal immunosuppressants

433 (37.2)

80 (23.6)

213 (38.7)

140 (51.1)

p < 0.001

 Corticosteroids

359 (30.9)

75 (22.1)

162 (29.5)

122 (44.5)

p < 0.001

 Monoclonal Antibodies

111 (9.5)

8 (2.4)

59 (10.7)

44 (16.1)

p < 0.001

 Intravenous Immunoglobulin

66 (5.7)

3 (0.9)

30 (5.5)

33 (12.0)

p < 0.001

 Subcutaneous Immunoglobulin

16 (1.4)

2 (0.6)

11 (2.0)

3 (1.1)

p = 0.223

 Plasmapheresis

12 (1.0)

1 (0.3)

2 (0.4)

9 (3.3)

p < 0.001